Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
97.0 GBX 1.50 ( 1.57%)
Last update at 2026-10-27T16:08:00Z
VOLUME
4302
Market Cap
61.08M
P/E
22.63

Momentum Score

…

ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
95.00
Low
97.00
High
52 Week Price Range
52.00
Low
116.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
95.50
Dividend Yield
-
Revenue TTM
85.81M
Revenue Per Share
1.27
Gross Profit TTM
42.10M
Debt / Equity
0.04
ROE
5.58%
Net Debt
-21.22M
ROCE
4.52%
Diluted EPS TTM
0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 4.01M 2.97M 4.44M 1.39M 20.28M
Minority interest -0.95M -0.96M -2.08M 0.02M 13.41M
Net income 1.69M 1.05M 3.09M -0.70M 16.65M
Selling general administrative 28.73M 29.39M 27.87M 22.91M 33.62M
Selling and marketing expenses - 2.15M - - -
Gross profit 35.91M 37.68M 38.38M 35.14M 53.62M
Reconciled depreciation 2.83M 2.79M 2.35M 1.99M 1.73M
Ebit 4.46M 3.74M 4.95M 3.76M 20.32M
Ebitda 7.29M 6.53M 7.45M 5.75M 22.21M
Depreciation and amortization 2.83M 2.79M 2.50M 1.99M 1.90M
Operating income 4.30M 3.54M 4.95M 3.76M 20.32M
Other operating expenses 75.30M 85.89M 80.36M 78.67M 85.29M
Interest expense 0.45M 0.76M 0.66M 0.28M 0.20M
Tax provision 1.38M 0.97M 1.35M 2.09M 3.63M
Interest income 0.11M 0.15M 0.10M 0.19M 0.13M
Net interest income -0.34M -0.61M -0.55M -0.09M -0.07M
Income tax expense 1.38M 0.97M 1.35M 2.09M 3.63M
Total revenue 79.60M 89.42M 85.31M 82.19M 105.61M
Total operating expenses 31.61M 34.15M 33.43M 31.61M 33.30M
Cost of revenue 43.68M 51.74M 46.94M 47.06M 51.99M
Total other income expense net -0.29M -0.56M -0.51M -2.37M -0.03M
Net income from continuing ops 2.63M 2.01M 3.09M -0.70M 16.65M
Net income applicable to common shares - - - -0.69M 8.16M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 120.60M 123.27M 121.31M 113.60M 116.62M
Intangible assets 23.90M 20.42M 17.71M 16.37M 18.18M
Other current assets 1.87M 3.23M - 28.64M 36.42M
Total liab 25.84M 29.89M 25.76M 19.25M 19.79M
Total stockholder equity 85.50M 83.69M 83.27M 82.06M 83.42M
Other current liab 10.29M 13.78M 15.16M 7.93M 10.17M
Common stock 3.39M 3.39M 3.38M 3.38M 3.38M
Capital stock 3.39M 3.39M 3.38M 3.38M 3.38M
Retained earnings 17.87M 15.82M 13.93M 12.41M 15.47M
Other liab - - - - 0.18M
Good will 17.93M 17.93M 17.93M 17.93M 17.93M
Other assets - - - 0.75M 0.30M
Cash 25.01M 22.37M 21.66M 14.31M 19.52M
Total current liabilities 21.81M 25.23M 22.17M 17.74M 18.40M
Current deferred revenue - 0.00M - - -
Net debt -21.22M -18.35M -17.18M -12.40M -18.00M
Short term debt 0.62M 0.65M 0.88M 0.40M 0.31M
Short long term debt - - - 0.00M 0.00M
Short long term debt total 3.79M 4.03M 4.48M 1.91M 1.52M
Other stockholder equity 63.39M 63.32M 65.96M 66.27M 64.57M
Property plant equipment - - - 5.24M 3.58M
Total current assets 69.94M 74.73M 74.49M 73.10M 76.45M
Net tangible assets - - - 47.76M 47.31M
Net receivables 28.52M 32.17M 24.81M 23.39M 35.50M
Inventory 14.55M 16.95M 22.41M 30.14M 20.50M
Accounts payable 9.79M 10.12M 6.12M 9.41M 7.92M
Accumulated other comprehensive income 0.85M 1.17M - - -2.82M
Common stock total equity - - - - 3.38M
Non currrent assets other - 20.42M 0.25M 0.44M 0.48M
Non current assets total 50.66M 48.53M 46.83M 40.50M 40.17M
Capital lease obligations 3.79M 4.03M 4.48M 1.91M 1.52M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -4.61M -3.42M -5.88M -2.69M -0.93M
Change to liabilities - - 0.00M -2.87M 0.75M
Total cashflows from investing activities -4.61M -3.42M - -2.69M -0.93M
Net borrowings - - - -0.37M -0.38M
Total cash from financing activities -1.95M -3.69M -2.40M -3.31M -0.68M
Change to operating activities - - - 1.39M 1.39M
Net income 4.01M 1.05M 4.44M 1.39M 20.28M
Change in cash 2.63M 0.72M 7.34M -5.21M 9.68M
Begin period cash flow 22.37M 21.66M 14.31M 19.52M 9.85M
End period cash flow 25.01M 22.37M 21.66M 14.31M 19.52M
Total cash from operating activities 10.45M 9.42M 15.91M -0.55M 11.98M
Issuance of capital stock 0.00M 0.01M 0.00M 0.06M 0.38M
Depreciation 2.83M 2.79M 2.35M 1.99M 1.73M
Other cashflows from investing activities -4.54M -2.91M - 0.19M 0.13M
Dividends paid 1.06M 2.81M 1.81M 2.89M 0.56M
Change to inventory 2.09M 4.74M 7.78M -8.59M -3.70M
Change to account receivables 4.16M -4.96M - 7.63M -3.96M
Sale purchase of stock - - - - 0.38M
Other cashflows from financing activities -0.89M -0.88M -0.59M -0.48M -0.50M
Change to netincome - - - 0.58M 9.00M
Capital expenditures 5.00M 4.62M 5.98M 2.89M 1.07M
Change in working capital 4.82M 2.79M 11.17M -2.43M -6.90M
Stock based compensation 0.40M 0.41M 0.41M 0.34M 0.12M
Other non cash items -1.61M 2.37M 0.55M -1.84M 0.07M
Free cash flow 5.44M 4.94M 9.93M -3.44M 10.91M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EAH
Eco Animal Health Group Plc
1.50
1.57%
97.00 22.63 24.04 0.71 0.73 0.56 4.99
HLN
Haleon PLC
-4.20
1.10%
376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC
4.00
0.24%
1704.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd
-2.00
0.95%
208.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics
-
-%
4.25 - 106.38 11.72 159.47 12.12 -4.15

Profile*

Eco Animal Health Group Plc

ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is based in London, the United Kingdom.

The Grange, London, United Kingdom, N14 6BN

44 208 447 8899

200

Name Title Year Born
Mr. Christopher Wilks ACA, BSc, F.C.A. CFO, Fin. Director, Sec. & Director 1964
Mr. David Charles Hallas CEO & Director 1964
Dr. David Charles Hallas CEO & Director 1964
Mr. Christopher John Wilks ACA, BSc, F.C.A. CFO, Finance Director, Secretary & Director 1964
Mr. Andrew Buglass Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…